Aytu BioPharma to Present at Upcoming October 2025 Conferences
-
Three killed in Taipei metro attacks, suspect dead
-
Seven Colombian soldiers killed in guerrilla attack: army
-
Amorim takes aim at Man Utd youth stars over 'entitlement'
-
Mercosur meets in Brazil, EU eyes January 12 trade deal
-
US Fed official says no urgency to cut rates, flags distorted data
-
Rome to charge visitors for access to Trevi Fountain
-
Spurs 'not a quick fix' for under-fire Frank
-
Poland president accuses Ukraine of not appreciating war support
-
Stocks advance with focus on central banks, tech
-
Amorim unfazed by 'Free Mainoo' T-shirt ahead of Villa clash
-
PSG penalty hero Safonov ended Intercontinental win with broken hand
-
French court rejects Shein suspension
-
'It's so much fun,' says Vonn as she milks her comeback
-
Moscow intent on pressing on in Ukraine: Putin
-
UN declares famine over in Gaza, says 'situation remains critical'
-
Guardiola 'excited' by Man City future, not pondering exit
-
Czechs name veteran coach Koubek for World Cup play-offs
-
PSG penalty hero Safonov out until next year with broken hand
-
Putin says ball in court of Russia's opponents in Ukraine talks
-
Czech Zabystran upsets Odermatt to claim Val Gardena super-G
-
NGOs fear 'catastrophic impact' of new Israel registration rules
-
US suspends green card lottery after MIT professor, Brown University killings
-
Arsenal in the 'right place' as Arteta marks six years at club
-
Sudan's El-Fasher under the RSF, destroyed and 'full of bodies'
-
From farms to court, climate-hit communities take on big polluters
-
Liverpool have 'moved on' from Salah furore, says upbeat Slot
-
Norway crown princess likely to undergo lung transplant
-
Iraq negotiates new coalition under US pressure
-
France's budget hits snag in setback for embattled PM
-
Putin hails Ukraine gains, threatens more, in annual press conference
-
US suspends green card lottery after Brown, MIT professor shootings
-
Chelsea's Maresca says Man City link '100 percent' speculation
-
Dominant Head moves into Bradman territory with fourth Adelaide ton
-
Arsenal battle to stay top of Christmas charts
-
Mexican low-cost airlines Volaris and Viva agree to merger
-
Border casinos caught in Thailand-Cambodia crossfire
-
Australia's Head slams unbeaten 142 to crush England's Ashes hopes
-
Epstein files due as US confronts long-delayed reckoning
-
'Not our enemy': Rush to rearm sparks backlash in east Germany
-
West Indies 110-0, trail by 465, after Conway's epic 227 for New Zealand
-
Arsonists target Bangladesh newspapers after student leader's death
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
-
Tears at tribute to firefighter killed in Hong Kong blaze
-
Seahawks edge Rams in overtime thriller to seize NFC lead
-
Teenager Flagg leads Mavericks to upset of Pistons
-
Australia's Head fires quickfire 68 as England's Ashes hopes fade
-
Japan hikes interest rates to 30-year-high
-
Brazil's top court strikes down law blocking Indigenous land claims
-
Conway falls for 227 as New Zealand pass 500 in West Indies Test
-
'We are ghosts': Britain's migrant night workers
NYSE - LSE
Aytu BioPharma to Present at Upcoming October 2025 Conferences
DENVER, CO / ACCESS Newswire / October 10, 2025 / DENVER, CO / ACCESS Newswire / October 10, 2025 /Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:
2025 Maxim Growth Summit
Date: October 22, 2025
Location: New York City
Investors should reach out to their Maxim sales representatives, or Robert Blum of Lytham Partners at [email protected] to schedule one-on-one meetings with Aytu's management.
Planet MicroCap Showcase: TORONTO 2025
Date: October 22, 2025 - October 23, 2025
Location: Toronto
Presentation Time: 2:30 p.m. Eastern time
Webcast: https://event.summitcast.com/view/34SFNFBix4cZpKNiohrXeh/eV26zB4GZpybjQPU4g6xja
If you would like to schedule one-on-one investor meetings with Aytu's management, and to attend the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub, please register here: REGISTER. Conversely, you can contact Robert Blum of Lytham Partners at [email protected] to assist in coordination.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
Ch.Havering--AMWN